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Effect of Treatment of Hemoperfusion on FGF23 and PTH Level in
Uremia Patients
Zhenhua Ji, Hua Zheng, Yi Sun, Xuemei Deng
Central Hospital, Shenyang Medical College, Shenyang, China
Objective: To study the change of FGF23, PTH and phosphorus level in
different frequency of hemoperfusion (HP) in uremic hemodialysis patients.
Methods: 60 maintenance hemodialysis (MHD) patients randomly divided
into three groups. 20 patients for HD + HP2 group, 20 patients for HD + HP3
and 20 patients for HD group. All patients accepted treatment of hemodial-
ysis for three times a week, HP + HD2 group were given hemodialysis three
times a week and one time of hemoperfusion for every two weeks.
HP + HD3 group were given hemodialysis three times a week and one time
of hemoperfusion for every 3 weeks. Test the serum calcium, phosphorus
FGF23 and PTH levels before and after the first time of HD and HP + HD treat-
ment. Test the same index after 12 weeks.
Results: After 12 weeks of treatment, (1) the phosphorus level of HD and
HP + HD group have no statistical significance (P > 0.05); (2) HP + HD2 serum
FGF23 and PTH decreased significantly, and the HD group or HP + HD1 group
has statistical significance (P < 0.05).
Conclusion: Every 2 weeks of hemoperfusion have the best effects on
clearing the serum FGF23 and PTH.Table Risk factors for chronic dialysis among patients with advanced
chronic kidney disease
Variables Hazard ratio (95%
confidence interval)
p value
Diabetes mellitus 1.80 (1.52e2.12) < 0.001
Hypertension 1.25 (1.10e1.42) < 0.001
Age, >60 vs. 60 years 1.29 (1.14e1.45) < 0.001
CCI score, >3 versus 3 1.26 (1.05e1.52) 0.0124
Medicine Hospitalization a 8.04 (7.02e9.20) < 0.001
Daily KA dosage (expressed as tablets) b
larger than 5.5 vs. Unsuitable dose
0.65 (0.43e1.00) 0.0492
ACEI use 0.63 (0.49e0.81) < 0.001
ARB use 0.65 (0.56e0.76) < 0.001
KA use 0.54 (0.47e0.62) < 0.001
Factors used in the Cox model: all covariates listed in the Table.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB,
angiotensin II receptor antagonist; CCI, Charlson Comorbidity Index;
KA, ketoanalog.
a Admitted under the internal medicine service within 30 days before the
outcome event.
b KA prescribed at fewer than 5.5 tablets daily is considered an unsuitablehttp://dx.doi.org/10.1016/j.hkjn.2015.09.164
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Association of All-cause Mortality in Chronic Kidney Disease Stage 3e5
Patients with Periodontitis in Uygur People in Xinjiang: A 6-year
Longitudinal, Observational Study
Li Zhang, Xiaohong Sang, Rasheeda Zakir, Suhua Li, Dilmurat Abula, Jing Li,
Shun Wang, Jian Liu
Department of Nephrology, The First Affiliated Hospital of Xinjiang Medical
University, Urumqi, China
Objective: In the past years, there has been documented the association of
periodontitis and chronic kidney disease (CKD). However, the association has
not investigated in Xinjiang in China. The aim of present study is to investi-
gate the association of periodontitis and CKD patients in above area.
Methods: A longitudinal, prospective, observational study was conducted in 15
villages in Moyu county in Xinjiang from 2007 to 2013. Two cross-sectional inves-
tigations were conducted in 2007 and 2013 respectively. A total 1072 CKD stage
3e5 patients with complete data collection were analyzed. The mean age was
38.7yearsold in2007,and44.7yearsold in2013.Theanalyzedvariables included
epidemiology, laboratorydata,andall-causemortality. Statisticalmethodswere
Student t-test, chi-square test, multivariate logistic regression model.
Results:TheprevalenceofCKD inperiodontitiswas6.4% in2007and9.8% in2013.
56 patientsweredead from2007e2013, the overall all-causemortalitywas4.0%.
The distribution of mortality rates in disease categories were 1.1% in non-peri-
odontitis-CKD cohort, 4.9% in periodontitis cohort, 7.2% in CKD cohort, 11.7% in
periodontitis-CKD cohort. Among periodontitis-CKD cohort, mortality rates
were 7.0% in periodontitis-proteinuria cohort, 9.1% in periodontitis-decreased
GFR cohort, and 50% in periodontitis-proteinuria-decreased GFR cohort.
Conclusion: Present study demonstrated high association of periodontitis
and CKD. Furthermore, all-cause mortality was aggravated by proteinuria
and decreased GFR in CKD patients with periodontitis.http://dx.doi.org/10.1016/j.hkjn.2015.09.165
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Ketoanalogs Supplementation Decreases Dialysis and Mortality Risk in
Patients with Advanced Chronic Kidney Disease
Che-Hsiung Wu1, Kwan-Dun Wu2, Vin-Cent Wu2
1Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taipei,
Taiwan
2National Taiwan University Hospital, Taipei, Taiwan
Background: The benefit of alpha-ketoanalogs (KA) supplementation for
advanced chronic kidney disease (CKD) patients that followed low-protein
diet (LPD) remains undetermined.Methods: We extracted longitudinal data for all advanced CKD patients in
the Taiwan National Health Insurance from 1 January 2000 through to 31
December 2010. A total of 1483 patients with advanced CKD treated with
LPD, who started KA supplementation, were enrolled in this study. We
analyzed the risks of end stage renal disease and all-cause mortality using
Cox proportional hazard models with influential drugs as time-dependent
variables.
Results: A total of 1113 events of initiating long-term dialysis and 1228
events of composite outcome occurred in patients with advanced CKD after
a mean follow-up of 1.57 years. Data analysis using the Cox model suggests
KA supplementation is associated with a lower risk for long-term dialysis
(HR, 0.54; 95% CI, 0.47e0.62) and the composite outcome of long-term dial-
ysis or death (HR, 0.49; 95% CI, 0.43e0.55) when daily dosage is more than
5.5 tablets. The beneficial effect was consistent in subgroup analysis, inde-
pendent of age, sex, and comorbidities.
Conclusion: Among advanced CKD patients that followed LPD, KA supple-
mentation at an appropriate dosage may substantially reduce the risk of
initiating long-term dialysis or of developing the composite outcome. KA
supplementation represents an additional therapeutic strategy to slow the
progression of CKD. The promising results in terms of mortality and
commencing chronic dialysis need confirmation with different study designs.dose.http://dx.doi.org/10.1016/j.hkjn.2015.09.166
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Association Between Serum 25-hydroxyvitamin D and Arterial Stiffness
in Non-dialysis-dependent CKD
Q. Luo, L. L. Wang, Y. H. Gao
Ningbo No. 2 Hospital, Ningbo, Zhejiang Province, China
Objective: 25-Hydroxyvitamin D [25(OH)D] deficiency are common in
chronic kidney disease (CKD) pupulation. This study aimed to investigate
the association between 25(OH)D and arterial stiffness in patients with
non-dialysis-dependent chronic kidney disease (CKD ND).
Methods: 283 patients aged 18 years with CKD ND were divided into two
groups: vitamin D deficient [25(OH)D < 20 ng/mL] and vitamin D non-defi-
cient [25(OH)D  20 ng/mL]. Brachial ankle pulse wave velocity (baPWV),
a good marker for arterial stiffness, was calculated.
Results: The prevalence of vitamin D deficiency was 58.3% (165/283) and the
mean concentration of 25(OH)Dwas 18 8 ng/ml. 25(OH)D inversely correlated
with baPWV. Multiple linear regression analysis showed that vitamin D level was
independently associated with baPWV in patients with CKD ND (b Z 0.18,
p< 0.001).Themodel accounted for 45% (R2Z0.45) of total varianceofbaPWV.
Conclusion: Vitamin D deficiency is common in CKD ND, and a low 25(OH)D
level is significantly associated with increased arterial stiffness.
